Safety and effectiveness of adalimumab in a clinical setting that reflects Canadian standard of care for the treatment of rheumatoid arthritis (RA): Results from the CanACT study

Table 2 American College of Rheumatology Core Components and Acute Phase Reactants

ACR Core Reactant	Components and Acute Phase	Baseline	Week 4	Week 8	Week 12
ACR Core Set	Tender joint count (0-68 scale)	14.9 ± 7.1	9.4 ± 7.1*	7.8 ± 7.1*	6.8 ± 6.8*
	Swollen joint count (0-66 scale)	13.2 ± 5.2	8.7 ± 5.6*	7.4 ± 5.5*	6.4 ± 5.2*
	Patient's assessment of pain, mm (0-100 mm VAS)^a	66.2 ± 22.3	45.0 ± 26.4*	40.3 ± 26.9*	37.3 ± 27.5*
	Patient's global assessment of disease activity, mm (0-100 mm VAS)^b	65.1 ± 22.7	45.1 ± 25.7*	41.0 ± 26.7*	37.4 ± 27.2*
	Physician's global assessment of disease activity, mm (0-100 mm VAS)^b	63.6 ± 17.6	40.7 ± 22.5*	33.5 ± 22.4*	29.0 ± 22.7*
	HAQ-DI score (0-3 scale)^c	1.5 ± 0.6	1.2 ± 0.7*	1.1 ± 0.7*	1.0 ± 0.7*
Acute Phase Reactant	ESR (mm/h) normal value < 20 mm/h	30.3 ± 23.8	20.6 ± 20.1*	20.7 ± 19.7*	20.0 ± 18.6*

*P < 0.001 vs. baseline.
^a0 = no pain and 100 = severe pain.
^b0 = no disease activity and 100 = extreme disease activity.
^c0 = no difficulty and 3 = unable to perform activity.
ACR: American College of Rheumatology; ESR: erythrocyte sedimentation rate; HAQ-DI: disability index of the health assessment questionnaire; VAS: visual analog scale.

ISSN: 1471-2474